nodes	percent_of_prediction	percent_of_DWPC	metapath
Darifenacin—Loperamide—Tamoxifen—pancreatic cancer	0.35	0.593	CrCrCtD
Darifenacin—Methadone—Tamoxifen—pancreatic cancer	0.24	0.407	CrCrCtD
Darifenacin—CYP2D6—Tamoxifen—pancreatic cancer	0.0236	0.203	CbGbCtD
Darifenacin—CYP2D6—Erlotinib—pancreatic cancer	0.02	0.173	CbGbCtD
Darifenacin—CYP3A4—Tamoxifen—pancreatic cancer	0.015	0.129	CbGbCtD
Darifenacin—CYP3A4—Erlotinib—pancreatic cancer	0.0127	0.11	CbGbCtD
Darifenacin—CYP3A4—Irinotecan—pancreatic cancer	0.0115	0.0993	CbGbCtD
Darifenacin—CYP2D6—Doxorubicin—pancreatic cancer	0.00988	0.0853	CbGbCtD
Darifenacin—CYP3A4—Docetaxel—pancreatic cancer	0.00843	0.0728	CbGbCtD
Darifenacin—CYP3A4—Sunitinib—pancreatic cancer	0.00839	0.0724	CbGbCtD
Darifenacin—CYP3A4—Doxorubicin—pancreatic cancer	0.00628	0.0543	CbGbCtD
Darifenacin—Face oedema—Epirubicin—pancreatic cancer	0.000347	0.00174	CcSEcCtD
Darifenacin—Eye disorder—Docetaxel—pancreatic cancer	0.000344	0.00173	CcSEcCtD
Darifenacin—Insomnia—Irinotecan—pancreatic cancer	0.000343	0.00172	CcSEcCtD
Darifenacin—Vomiting—Tamoxifen—pancreatic cancer	0.000341	0.00171	CcSEcCtD
Darifenacin—Cerebrovascular accident—Doxorubicin—pancreatic cancer	0.000339	0.0017	CcSEcCtD
Darifenacin—Hypersensitivity—Sunitinib—pancreatic cancer	0.000339	0.0017	CcSEcCtD
Darifenacin—Rash—Tamoxifen—pancreatic cancer	0.000339	0.0017	CcSEcCtD
Darifenacin—Dermatitis—Tamoxifen—pancreatic cancer	0.000338	0.0017	CcSEcCtD
Darifenacin—Vomiting—Erlotinib—pancreatic cancer	0.000338	0.0017	CcSEcCtD
Darifenacin—Dyspnoea—Irinotecan—pancreatic cancer	0.000338	0.0017	CcSEcCtD
Darifenacin—Somnolence—Irinotecan—pancreatic cancer	0.000337	0.00169	CcSEcCtD
Darifenacin—Headache—Tamoxifen—pancreatic cancer	0.000336	0.00169	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.000336	0.00169	CcSEcCtD
Darifenacin—Rash—Erlotinib—pancreatic cancer	0.000335	0.00168	CcSEcCtD
Darifenacin—Dermatitis—Erlotinib—pancreatic cancer	0.000335	0.00168	CcSEcCtD
Darifenacin—Angiopathy—Docetaxel—pancreatic cancer	0.000334	0.00168	CcSEcCtD
Darifenacin—Insomnia—Gemcitabine—pancreatic cancer	0.000334	0.00168	CcSEcCtD
Darifenacin—Dyspepsia—Irinotecan—pancreatic cancer	0.000333	0.00167	CcSEcCtD
Darifenacin—Headache—Erlotinib—pancreatic cancer	0.000333	0.00167	CcSEcCtD
Darifenacin—Mediastinal disorder—Docetaxel—pancreatic cancer	0.000332	0.00167	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.000331	0.00166	CcSEcCtD
Darifenacin—Asthenia—Sunitinib—pancreatic cancer	0.00033	0.00166	CcSEcCtD
Darifenacin—Dry skin—Epirubicin—pancreatic cancer	0.000329	0.00165	CcSEcCtD
Darifenacin—Dyspnoea—Gemcitabine—pancreatic cancer	0.000329	0.00165	CcSEcCtD
Darifenacin—Insomnia—Fluorouracil—pancreatic cancer	0.000328	0.00165	CcSEcCtD
Darifenacin—Somnolence—Gemcitabine—pancreatic cancer	0.000328	0.00165	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000327	0.00164	CcSEcCtD
Darifenacin—Pruritus—Sunitinib—pancreatic cancer	0.000325	0.00163	CcSEcCtD
Darifenacin—Breast disorder—Epirubicin—pancreatic cancer	0.000325	0.00163	CcSEcCtD
Darifenacin—Constipation—Irinotecan—pancreatic cancer	0.000324	0.00163	CcSEcCtD
Darifenacin—Pain—Irinotecan—pancreatic cancer	0.000324	0.00163	CcSEcCtD
Darifenacin—Aspartate aminotransferase increased—Epirubicin—pancreatic cancer	0.000324	0.00162	CcSEcCtD
Darifenacin—Dyspnoea—Fluorouracil—pancreatic cancer	0.000324	0.00162	CcSEcCtD
Darifenacin—Mental disorder—Docetaxel—pancreatic cancer	0.000323	0.00162	CcSEcCtD
Darifenacin—Somnolence—Fluorouracil—pancreatic cancer	0.000323	0.00162	CcSEcCtD
Darifenacin—Face oedema—Doxorubicin—pancreatic cancer	0.000321	0.00161	CcSEcCtD
Darifenacin—Dyspepsia—Fluorouracil—pancreatic cancer	0.000319	0.0016	CcSEcCtD
Darifenacin—Nausea—Tamoxifen—pancreatic cancer	0.000319	0.0016	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000319	0.0016	CcSEcCtD
Darifenacin—Alanine aminotransferase increased—Epirubicin—pancreatic cancer	0.000317	0.00159	CcSEcCtD
Darifenacin—Constipation—Gemcitabine—pancreatic cancer	0.000316	0.00158	CcSEcCtD
Darifenacin—Pain—Gemcitabine—pancreatic cancer	0.000316	0.00158	CcSEcCtD
Darifenacin—Nausea—Erlotinib—pancreatic cancer	0.000316	0.00158	CcSEcCtD
Darifenacin—Diarrhoea—Sunitinib—pancreatic cancer	0.000315	0.00158	CcSEcCtD
Darifenacin—Dysgeusia—Docetaxel—pancreatic cancer	0.000314	0.00158	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000313	0.00157	CcSEcCtD
Darifenacin—Feeling abnormal—Irinotecan—pancreatic cancer	0.000312	0.00157	CcSEcCtD
Darifenacin—Influenza—Epirubicin—pancreatic cancer	0.000311	0.00156	CcSEcCtD
Darifenacin—Back pain—Docetaxel—pancreatic cancer	0.00031	0.00156	CcSEcCtD
Darifenacin—Pain—Fluorouracil—pancreatic cancer	0.00031	0.00156	CcSEcCtD
Darifenacin—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.00031	0.00156	CcSEcCtD
Darifenacin—Dry skin—Doxorubicin—pancreatic cancer	0.000305	0.00153	CcSEcCtD
Darifenacin—Dizziness—Sunitinib—pancreatic cancer	0.000304	0.00153	CcSEcCtD
Darifenacin—Feeling abnormal—Gemcitabine—pancreatic cancer	0.000304	0.00153	CcSEcCtD
Darifenacin—Breast disorder—Doxorubicin—pancreatic cancer	0.000301	0.00151	CcSEcCtD
Darifenacin—Abdominal pain—Irinotecan—pancreatic cancer	0.000299	0.0015	CcSEcCtD
Darifenacin—Aspartate aminotransferase increased—Doxorubicin—pancreatic cancer	0.000299	0.0015	CcSEcCtD
Darifenacin—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000299	0.0015	CcSEcCtD
Darifenacin—Bronchitis—Epirubicin—pancreatic cancer	0.000299	0.0015	CcSEcCtD
Darifenacin—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	0.000293	0.00147	CcSEcCtD
Darifenacin—Vomiting—Sunitinib—pancreatic cancer	0.000292	0.00147	CcSEcCtD
Darifenacin—Rash—Sunitinib—pancreatic cancer	0.00029	0.00146	CcSEcCtD
Darifenacin—Dermatitis—Sunitinib—pancreatic cancer	0.00029	0.00145	CcSEcCtD
Darifenacin—Headache—Sunitinib—pancreatic cancer	0.000288	0.00145	CcSEcCtD
Darifenacin—Syncope—Docetaxel—pancreatic cancer	0.000288	0.00144	CcSEcCtD
Darifenacin—Influenza—Doxorubicin—pancreatic cancer	0.000287	0.00144	CcSEcCtD
Darifenacin—Palpitations—Docetaxel—pancreatic cancer	0.000284	0.00142	CcSEcCtD
Darifenacin—Weight increased—Epirubicin—pancreatic cancer	0.000283	0.00142	CcSEcCtD
Darifenacin—Loss of consciousness—Docetaxel—pancreatic cancer	0.000282	0.00142	CcSEcCtD
Darifenacin—Cough—Docetaxel—pancreatic cancer	0.00028	0.00141	CcSEcCtD
Darifenacin—Hypersensitivity—Irinotecan—pancreatic cancer	0.000279	0.0014	CcSEcCtD
Darifenacin—Hypertension—Docetaxel—pancreatic cancer	0.000277	0.00139	CcSEcCtD
Darifenacin—Infestation NOS—Epirubicin—pancreatic cancer	0.000277	0.00139	CcSEcCtD
Darifenacin—Infestation—Epirubicin—pancreatic cancer	0.000277	0.00139	CcSEcCtD
Darifenacin—Bronchitis—Doxorubicin—pancreatic cancer	0.000276	0.00139	CcSEcCtD
Darifenacin—Arthralgia—Docetaxel—pancreatic cancer	0.000273	0.00137	CcSEcCtD
Darifenacin—Nausea—Sunitinib—pancreatic cancer	0.000273	0.00137	CcSEcCtD
Darifenacin—Asthenia—Irinotecan—pancreatic cancer	0.000272	0.00136	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000271	0.00136	CcSEcCtD
Darifenacin—Stomatitis—Epirubicin—pancreatic cancer	0.00027	0.00136	CcSEcCtD
Darifenacin—Urinary tract infection—Epirubicin—pancreatic cancer	0.000269	0.00135	CcSEcCtD
Darifenacin—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000267	0.00134	CcSEcCtD
Darifenacin—Dry mouth—Docetaxel—pancreatic cancer	0.000267	0.00134	CcSEcCtD
Darifenacin—Sweating—Epirubicin—pancreatic cancer	0.000266	0.00133	CcSEcCtD
Darifenacin—Asthenia—Gemcitabine—pancreatic cancer	0.000265	0.00133	CcSEcCtD
Darifenacin—Confusional state—Docetaxel—pancreatic cancer	0.000264	0.00133	CcSEcCtD
Darifenacin—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000262	0.00131	CcSEcCtD
Darifenacin—Oedema—Docetaxel—pancreatic cancer	0.000262	0.00131	CcSEcCtD
Darifenacin—Weight increased—Doxorubicin—pancreatic cancer	0.000262	0.00131	CcSEcCtD
Darifenacin—Pruritus—Gemcitabine—pancreatic cancer	0.000261	0.00131	CcSEcCtD
Darifenacin—Infection—Docetaxel—pancreatic cancer	0.00026	0.00131	CcSEcCtD
Darifenacin—Sinusitis—Epirubicin—pancreatic cancer	0.00026	0.0013	CcSEcCtD
Darifenacin—Diarrhoea—Irinotecan—pancreatic cancer	0.000259	0.0013	CcSEcCtD
Darifenacin—Shock—Docetaxel—pancreatic cancer	0.000258	0.00129	CcSEcCtD
Darifenacin—Nervous system disorder—Docetaxel—pancreatic cancer	0.000257	0.00129	CcSEcCtD
Darifenacin—Pruritus—Fluorouracil—pancreatic cancer	0.000257	0.00129	CcSEcCtD
Darifenacin—Infestation—Doxorubicin—pancreatic cancer	0.000256	0.00129	CcSEcCtD
Darifenacin—Infestation NOS—Doxorubicin—pancreatic cancer	0.000256	0.00129	CcSEcCtD
Darifenacin—Tachycardia—Docetaxel—pancreatic cancer	0.000256	0.00128	CcSEcCtD
Darifenacin—Skin disorder—Docetaxel—pancreatic cancer	0.000254	0.00128	CcSEcCtD
Darifenacin—Diarrhoea—Gemcitabine—pancreatic cancer	0.000253	0.00127	CcSEcCtD
Darifenacin—Dizziness—Irinotecan—pancreatic cancer	0.000251	0.00126	CcSEcCtD
Darifenacin—Stomatitis—Doxorubicin—pancreatic cancer	0.00025	0.00125	CcSEcCtD
Darifenacin—Rhinitis—Epirubicin—pancreatic cancer	0.000249	0.00125	CcSEcCtD
Darifenacin—Urinary tract infection—Doxorubicin—pancreatic cancer	0.000249	0.00125	CcSEcCtD
Darifenacin—Diarrhoea—Fluorouracil—pancreatic cancer	0.000248	0.00125	CcSEcCtD
Darifenacin—Pharyngitis—Epirubicin—pancreatic cancer	0.000247	0.00124	CcSEcCtD
Darifenacin—Sweating—Doxorubicin—pancreatic cancer	0.000246	0.00123	CcSEcCtD
Darifenacin—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000246	0.00123	CcSEcCtD
Darifenacin—Oedema peripheral—Epirubicin—pancreatic cancer	0.000245	0.00123	CcSEcCtD
Darifenacin—Urethral disorder—Epirubicin—pancreatic cancer	0.000244	0.00122	CcSEcCtD
Darifenacin—Vomiting—Irinotecan—pancreatic cancer	0.000241	0.00121	CcSEcCtD
Darifenacin—Sinusitis—Doxorubicin—pancreatic cancer	0.00024	0.00121	CcSEcCtD
Darifenacin—Dizziness—Fluorouracil—pancreatic cancer	0.00024	0.0012	CcSEcCtD
Darifenacin—Visual impairment—Epirubicin—pancreatic cancer	0.00024	0.0012	CcSEcCtD
Darifenacin—Rash—Irinotecan—pancreatic cancer	0.000239	0.0012	CcSEcCtD
Darifenacin—Dermatitis—Irinotecan—pancreatic cancer	0.000239	0.0012	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000239	0.0012	CcSEcCtD
Darifenacin—Headache—Irinotecan—pancreatic cancer	0.000237	0.00119	CcSEcCtD
Darifenacin—Insomnia—Docetaxel—pancreatic cancer	0.000237	0.00119	CcSEcCtD
Darifenacin—Erythema multiforme—Epirubicin—pancreatic cancer	0.000235	0.00118	CcSEcCtD
Darifenacin—Vomiting—Gemcitabine—pancreatic cancer	0.000235	0.00118	CcSEcCtD
Darifenacin—Dyspnoea—Docetaxel—pancreatic cancer	0.000233	0.00117	CcSEcCtD
Darifenacin—Somnolence—Docetaxel—pancreatic cancer	0.000233	0.00117	CcSEcCtD
Darifenacin—Rash—Gemcitabine—pancreatic cancer	0.000233	0.00117	CcSEcCtD
Darifenacin—Dermatitis—Gemcitabine—pancreatic cancer	0.000232	0.00117	CcSEcCtD
Darifenacin—Eye disorder—Epirubicin—pancreatic cancer	0.000232	0.00117	CcSEcCtD
Darifenacin—Headache—Gemcitabine—pancreatic cancer	0.000231	0.00116	CcSEcCtD
Darifenacin—Vomiting—Fluorouracil—pancreatic cancer	0.000231	0.00116	CcSEcCtD
Darifenacin—Rhinitis—Doxorubicin—pancreatic cancer	0.000231	0.00116	CcSEcCtD
Darifenacin—Dyspepsia—Docetaxel—pancreatic cancer	0.000231	0.00116	CcSEcCtD
Darifenacin—Rash—Fluorouracil—pancreatic cancer	0.000229	0.00115	CcSEcCtD
Darifenacin—Dermatitis—Fluorouracil—pancreatic cancer	0.000229	0.00115	CcSEcCtD
Darifenacin—Pharyngitis—Doxorubicin—pancreatic cancer	0.000228	0.00115	CcSEcCtD
Darifenacin—Headache—Fluorouracil—pancreatic cancer	0.000227	0.00114	CcSEcCtD
Darifenacin—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.000227	0.00114	CcSEcCtD
Darifenacin—Oedema peripheral—Doxorubicin—pancreatic cancer	0.000227	0.00114	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000226	0.00114	CcSEcCtD
Darifenacin—Angiopathy—Epirubicin—pancreatic cancer	0.000226	0.00113	CcSEcCtD
Darifenacin—Urethral disorder—Doxorubicin—pancreatic cancer	0.000226	0.00113	CcSEcCtD
Darifenacin—Nausea—Irinotecan—pancreatic cancer	0.000225	0.00113	CcSEcCtD
Darifenacin—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000224	0.00112	CcSEcCtD
Darifenacin—Pain—Docetaxel—pancreatic cancer	0.000224	0.00112	CcSEcCtD
Darifenacin—Constipation—Docetaxel—pancreatic cancer	0.000224	0.00112	CcSEcCtD
Darifenacin—Visual impairment—Doxorubicin—pancreatic cancer	0.000222	0.00111	CcSEcCtD
Darifenacin—Nausea—Gemcitabine—pancreatic cancer	0.000219	0.0011	CcSEcCtD
Darifenacin—Mental disorder—Epirubicin—pancreatic cancer	0.000218	0.00109	CcSEcCtD
Darifenacin—Erythema multiforme—Doxorubicin—pancreatic cancer	0.000218	0.00109	CcSEcCtD
Darifenacin—Feeling abnormal—Docetaxel—pancreatic cancer	0.000216	0.00108	CcSEcCtD
Darifenacin—Nausea—Fluorouracil—pancreatic cancer	0.000216	0.00108	CcSEcCtD
Darifenacin—Eye disorder—Doxorubicin—pancreatic cancer	0.000215	0.00108	CcSEcCtD
Darifenacin—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000214	0.00108	CcSEcCtD
Darifenacin—Flatulence—Epirubicin—pancreatic cancer	0.000213	0.00107	CcSEcCtD
Darifenacin—Dysgeusia—Epirubicin—pancreatic cancer	0.000212	0.00106	CcSEcCtD
Darifenacin—Back pain—Epirubicin—pancreatic cancer	0.000209	0.00105	CcSEcCtD
Darifenacin—Angiopathy—Doxorubicin—pancreatic cancer	0.000209	0.00105	CcSEcCtD
Darifenacin—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.000207	0.00104	CcSEcCtD
Darifenacin—Abdominal pain—Docetaxel—pancreatic cancer	0.000207	0.00104	CcSEcCtD
Darifenacin—Vision blurred—Epirubicin—pancreatic cancer	0.000204	0.00102	CcSEcCtD
Darifenacin—Mental disorder—Doxorubicin—pancreatic cancer	0.000202	0.00101	CcSEcCtD
Darifenacin—Flatulence—Doxorubicin—pancreatic cancer	0.000197	0.000991	CcSEcCtD
Darifenacin—Dysgeusia—Doxorubicin—pancreatic cancer	0.000196	0.000985	CcSEcCtD
Darifenacin—Syncope—Epirubicin—pancreatic cancer	0.000194	0.000974	CcSEcCtD
Darifenacin—Back pain—Doxorubicin—pancreatic cancer	0.000194	0.000972	CcSEcCtD
Darifenacin—Hypersensitivity—Docetaxel—pancreatic cancer	0.000193	0.000969	CcSEcCtD
Darifenacin—Palpitations—Epirubicin—pancreatic cancer	0.000191	0.00096	CcSEcCtD
Darifenacin—Loss of consciousness—Epirubicin—pancreatic cancer	0.00019	0.000955	CcSEcCtD
Darifenacin—Cough—Epirubicin—pancreatic cancer	0.000189	0.000948	CcSEcCtD
Darifenacin—Vision blurred—Doxorubicin—pancreatic cancer	0.000189	0.000947	CcSEcCtD
Darifenacin—Asthenia—Docetaxel—pancreatic cancer	0.000188	0.000943	CcSEcCtD
Darifenacin—Hypertension—Epirubicin—pancreatic cancer	0.000187	0.000938	CcSEcCtD
Darifenacin—Pruritus—Docetaxel—pancreatic cancer	0.000185	0.00093	CcSEcCtD
Darifenacin—Arthralgia—Epirubicin—pancreatic cancer	0.000184	0.000925	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000183	0.000919	CcSEcCtD
Darifenacin—Dry mouth—Epirubicin—pancreatic cancer	0.00018	0.000905	CcSEcCtD
Darifenacin—Syncope—Doxorubicin—pancreatic cancer	0.00018	0.000902	CcSEcCtD
Darifenacin—Diarrhoea—Docetaxel—pancreatic cancer	0.000179	0.0009	CcSEcCtD
Darifenacin—Confusional state—Epirubicin—pancreatic cancer	0.000178	0.000894	CcSEcCtD
Darifenacin—Palpitations—Doxorubicin—pancreatic cancer	0.000177	0.000888	CcSEcCtD
Darifenacin—Oedema—Epirubicin—pancreatic cancer	0.000177	0.000887	CcSEcCtD
Darifenacin—Anaphylactic shock—Epirubicin—pancreatic cancer	0.000177	0.000887	CcSEcCtD
Darifenacin—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000176	0.000884	CcSEcCtD
Darifenacin—Infection—Epirubicin—pancreatic cancer	0.000175	0.000881	CcSEcCtD
Darifenacin—Cough—Doxorubicin—pancreatic cancer	0.000175	0.000877	CcSEcCtD
Darifenacin—Shock—Epirubicin—pancreatic cancer	0.000174	0.000872	CcSEcCtD
Darifenacin—Nervous system disorder—Epirubicin—pancreatic cancer	0.000173	0.00087	CcSEcCtD
Darifenacin—Dizziness—Docetaxel—pancreatic cancer	0.000173	0.000869	CcSEcCtD
Darifenacin—Hypertension—Doxorubicin—pancreatic cancer	0.000173	0.000868	CcSEcCtD
Darifenacin—Tachycardia—Epirubicin—pancreatic cancer	0.000172	0.000865	CcSEcCtD
Darifenacin—Skin disorder—Epirubicin—pancreatic cancer	0.000172	0.000861	CcSEcCtD
Darifenacin—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000171	0.000857	CcSEcCtD
Darifenacin—Arthralgia—Doxorubicin—pancreatic cancer	0.000171	0.000856	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000169	0.00085	CcSEcCtD
Darifenacin—Dry mouth—Doxorubicin—pancreatic cancer	0.000167	0.000837	CcSEcCtD
Darifenacin—Vomiting—Docetaxel—pancreatic cancer	0.000167	0.000836	CcSEcCtD
Darifenacin—Rash—Docetaxel—pancreatic cancer	0.000165	0.000829	CcSEcCtD
Darifenacin—Dermatitis—Docetaxel—pancreatic cancer	0.000165	0.000828	CcSEcCtD
Darifenacin—Confusional state—Doxorubicin—pancreatic cancer	0.000165	0.000827	CcSEcCtD
Darifenacin—Headache—Docetaxel—pancreatic cancer	0.000164	0.000824	CcSEcCtD
Darifenacin—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.000163	0.000821	CcSEcCtD
Darifenacin—Oedema—Doxorubicin—pancreatic cancer	0.000163	0.000821	CcSEcCtD
Darifenacin—Infection—Doxorubicin—pancreatic cancer	0.000162	0.000815	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000161	0.000808	CcSEcCtD
Darifenacin—Shock—Doxorubicin—pancreatic cancer	0.000161	0.000807	CcSEcCtD
Darifenacin—Nervous system disorder—Doxorubicin—pancreatic cancer	0.00016	0.000805	CcSEcCtD
Darifenacin—Insomnia—Epirubicin—pancreatic cancer	0.00016	0.000802	CcSEcCtD
Darifenacin—Tachycardia—Doxorubicin—pancreatic cancer	0.00016	0.000801	CcSEcCtD
Darifenacin—Skin disorder—Doxorubicin—pancreatic cancer	0.000159	0.000797	CcSEcCtD
Darifenacin—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.000158	0.000793	CcSEcCtD
Darifenacin—Dyspnoea—Epirubicin—pancreatic cancer	0.000157	0.000791	CcSEcCtD
Darifenacin—Somnolence—Epirubicin—pancreatic cancer	0.000157	0.000788	CcSEcCtD
Darifenacin—Nausea—Docetaxel—pancreatic cancer	0.000156	0.000781	CcSEcCtD
Darifenacin—Dyspepsia—Epirubicin—pancreatic cancer	0.000155	0.000781	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000153	0.000766	CcSEcCtD
Darifenacin—Pain—Epirubicin—pancreatic cancer	0.000151	0.000758	CcSEcCtD
Darifenacin—Constipation—Epirubicin—pancreatic cancer	0.000151	0.000758	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000149	0.000748	CcSEcCtD
Darifenacin—Insomnia—Doxorubicin—pancreatic cancer	0.000148	0.000742	CcSEcCtD
Darifenacin—Dyspnoea—Doxorubicin—pancreatic cancer	0.000146	0.000732	CcSEcCtD
Darifenacin—Feeling abnormal—Epirubicin—pancreatic cancer	0.000146	0.000731	CcSEcCtD
Darifenacin—Somnolence—Doxorubicin—pancreatic cancer	0.000145	0.000729	CcSEcCtD
Darifenacin—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000144	0.000725	CcSEcCtD
Darifenacin—Dyspepsia—Doxorubicin—pancreatic cancer	0.000144	0.000722	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000141	0.000708	CcSEcCtD
Darifenacin—Constipation—Doxorubicin—pancreatic cancer	0.00014	0.000702	CcSEcCtD
Darifenacin—Pain—Doxorubicin—pancreatic cancer	0.00014	0.000702	CcSEcCtD
Darifenacin—Abdominal pain—Epirubicin—pancreatic cancer	0.00014	0.000701	CcSEcCtD
Darifenacin—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000135	0.000676	CcSEcCtD
Darifenacin—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000134	0.000671	CcSEcCtD
Darifenacin—Hypersensitivity—Epirubicin—pancreatic cancer	0.00013	0.000653	CcSEcCtD
Darifenacin—Abdominal pain—Doxorubicin—pancreatic cancer	0.000129	0.000649	CcSEcCtD
Darifenacin—Asthenia—Epirubicin—pancreatic cancer	0.000127	0.000636	CcSEcCtD
Darifenacin—Pruritus—Epirubicin—pancreatic cancer	0.000125	0.000627	CcSEcCtD
Darifenacin—Diarrhoea—Epirubicin—pancreatic cancer	0.000121	0.000607	CcSEcCtD
Darifenacin—Hypersensitivity—Doxorubicin—pancreatic cancer	0.00012	0.000605	CcSEcCtD
Darifenacin—Asthenia—Doxorubicin—pancreatic cancer	0.000117	0.000589	CcSEcCtD
Darifenacin—Dizziness—Epirubicin—pancreatic cancer	0.000117	0.000586	CcSEcCtD
Darifenacin—Pruritus—Doxorubicin—pancreatic cancer	0.000116	0.000581	CcSEcCtD
Darifenacin—Vomiting—Epirubicin—pancreatic cancer	0.000112	0.000564	CcSEcCtD
Darifenacin—Diarrhoea—Doxorubicin—pancreatic cancer	0.000112	0.000561	CcSEcCtD
Darifenacin—Rash—Epirubicin—pancreatic cancer	0.000111	0.000559	CcSEcCtD
Darifenacin—Dermatitis—Epirubicin—pancreatic cancer	0.000111	0.000559	CcSEcCtD
Darifenacin—Headache—Epirubicin—pancreatic cancer	0.000111	0.000556	CcSEcCtD
Darifenacin—Dizziness—Doxorubicin—pancreatic cancer	0.000108	0.000543	CcSEcCtD
Darifenacin—Nausea—Epirubicin—pancreatic cancer	0.000105	0.000527	CcSEcCtD
Darifenacin—Vomiting—Doxorubicin—pancreatic cancer	0.000104	0.000522	CcSEcCtD
Darifenacin—Rash—Doxorubicin—pancreatic cancer	0.000103	0.000517	CcSEcCtD
Darifenacin—Dermatitis—Doxorubicin—pancreatic cancer	0.000103	0.000517	CcSEcCtD
Darifenacin—Headache—Doxorubicin—pancreatic cancer	0.000102	0.000514	CcSEcCtD
Darifenacin—Nausea—Doxorubicin—pancreatic cancer	9.71e-05	0.000487	CcSEcCtD
Darifenacin—CHRM3—Metabolism—TYMS—pancreatic cancer	2.06e-05	0.000219	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—PIK3CD—pancreatic cancer	2.05e-05	0.000218	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—SLC2A2—pancreatic cancer	2.05e-05	0.000218	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—HIF1A—pancreatic cancer	2.04e-05	0.000217	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—KDR—pancreatic cancer	2.04e-05	0.000217	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—TSC2—pancreatic cancer	2.04e-05	0.000216	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ARG2—pancreatic cancer	2.04e-05	0.000216	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—AGTR1—pancreatic cancer	2.04e-05	0.000216	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—AGTR1—pancreatic cancer	2.03e-05	0.000216	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—AGTR1—pancreatic cancer	2.01e-05	0.000214	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—STK11—pancreatic cancer	2.01e-05	0.000213	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—STK11—pancreatic cancer	2e-05	0.000213	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—APOE—pancreatic cancer	2e-05	0.000212	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—STK11—pancreatic cancer	1.98e-05	0.00021	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—KDR—pancreatic cancer	1.96e-05	0.000208	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—NFKBIA—pancreatic cancer	1.94e-05	0.000206	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—NOTCH1—pancreatic cancer	1.92e-05	0.000204	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—PIK3CD—pancreatic cancer	1.89e-05	0.0002	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—PIK3CD—pancreatic cancer	1.88e-05	0.0002	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—PIK3CG—pancreatic cancer	1.88e-05	0.0002	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—NRAS—pancreatic cancer	1.88e-05	0.0002	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—PIK3CD—pancreatic cancer	1.86e-05	0.000198	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—NFKBIA—pancreatic cancer	1.86e-05	0.000197	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—EGF—pancreatic cancer	1.86e-05	0.000197	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—NOTCH1—pancreatic cancer	1.84e-05	0.000196	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—PIK3CB—pancreatic cancer	1.81e-05	0.000192	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—PIK3CB—pancreatic cancer	1.81e-05	0.000192	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—PIK3CG—pancreatic cancer	1.8e-05	0.000191	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—NRAS—pancreatic cancer	1.8e-05	0.000191	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—PIK3CB—pancreatic cancer	1.79e-05	0.00019	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—TYMP—pancreatic cancer	1.78e-05	0.000189	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—EGF—pancreatic cancer	1.78e-05	0.000189	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—SMAD4—pancreatic cancer	1.76e-05	0.000187	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—SMAD4—pancreatic cancer	1.75e-05	0.000186	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—CXCL8—pancreatic cancer	1.74e-05	0.000185	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—SMAD4—pancreatic cancer	1.74e-05	0.000184	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—CXCL8—pancreatic cancer	1.74e-05	0.000184	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—CXCL8—pancreatic cancer	1.72e-05	0.000182	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—HES1—pancreatic cancer	1.72e-05	0.000182	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—EGFR—pancreatic cancer	1.71e-05	0.000182	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—HES1—pancreatic cancer	1.71e-05	0.000182	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—HES1—pancreatic cancer	1.7e-05	0.00018	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—APOE—pancreatic cancer	1.68e-05	0.000178	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—PIK3CD—pancreatic cancer	1.65e-05	0.000176	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—PIK3CB—pancreatic cancer	1.65e-05	0.000175	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—EGFR—pancreatic cancer	1.64e-05	0.000174	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—PIK3CB—pancreatic cancer	1.64e-05	0.000174	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.64e-05	0.000174	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—PIK3CB—pancreatic cancer	1.62e-05	0.000172	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—KRAS—pancreatic cancer	1.62e-05	0.000172	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—CD44—pancreatic cancer	1.59e-05	0.000169	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—PIK3CD—pancreatic cancer	1.58e-05	0.000168	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—CXCL8—pancreatic cancer	1.58e-05	0.000168	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—CXCL8—pancreatic cancer	1.58e-05	0.000167	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.57e-05	0.000166	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—CXCL8—pancreatic cancer	1.56e-05	0.000166	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—KRAS—pancreatic cancer	1.55e-05	0.000165	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—GCG—pancreatic cancer	1.52e-05	0.000162	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PIK3CG—pancreatic cancer	1.51e-05	0.00016	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—TERT—pancreatic cancer	1.51e-05	0.00016	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—TERT—pancreatic cancer	1.5e-05	0.000159	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—PIK3CA—pancreatic cancer	1.49e-05	0.000158	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—TERT—pancreatic cancer	1.49e-05	0.000158	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PPARG—pancreatic cancer	1.46e-05	0.000155	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—PIK3CB—pancreatic cancer	1.44e-05	0.000153	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—HIF1A—pancreatic cancer	1.44e-05	0.000153	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GLP1R—pancreatic cancer	1.44e-05	0.000152	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—TSC2—pancreatic cancer	1.44e-05	0.000152	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—HIF1A—pancreatic cancer	1.43e-05	0.000152	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—STK11—pancreatic cancer	1.43e-05	0.000152	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—TSC2—pancreatic cancer	1.43e-05	0.000152	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—PIK3CA—pancreatic cancer	1.42e-05	0.000151	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—HIF1A—pancreatic cancer	1.42e-05	0.000151	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—TSC2—pancreatic cancer	1.42e-05	0.00015	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—DPYD—pancreatic cancer	1.41e-05	0.00015	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—APOE—pancreatic cancer	1.41e-05	0.000149	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—APOE—pancreatic cancer	1.4e-05	0.000149	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—APOE—pancreatic cancer	1.39e-05	0.000147	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CXCL8—pancreatic cancer	1.38e-05	0.000147	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—PIK3CB—pancreatic cancer	1.38e-05	0.000147	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—KDR—pancreatic cancer	1.38e-05	0.000146	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—HRAS—pancreatic cancer	1.38e-05	0.000146	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—KDR—pancreatic cancer	1.37e-05	0.000146	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—KDR—pancreatic cancer	1.36e-05	0.000144	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	1.34e-05	0.000142	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—AKT1—pancreatic cancer	1.34e-05	0.000142	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PIK3CD—pancreatic cancer	1.33e-05	0.000141	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CXCL8—pancreatic cancer	1.33e-05	0.000141	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CASP3—pancreatic cancer	1.33e-05	0.000141	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—HRAS—pancreatic cancer	1.32e-05	0.00014	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—NFKBIA—pancreatic cancer	1.31e-05	0.000139	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—NFKBIA—pancreatic cancer	1.31e-05	0.000139	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—NOTCH1—pancreatic cancer	1.3e-05	0.000138	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—NOTCH1—pancreatic cancer	1.29e-05	0.000137	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—NFKBIA—pancreatic cancer	1.29e-05	0.000137	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CCND1—pancreatic cancer	1.29e-05	0.000137	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—AKT1—pancreatic cancer	1.28e-05	0.000136	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—NOTCH1—pancreatic cancer	1.28e-05	0.000136	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CTNNB1—pancreatic cancer	1.28e-05	0.000136	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CASP3—pancreatic cancer	1.27e-05	0.000135	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PIK3CG—pancreatic cancer	1.27e-05	0.000135	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—NRAS—pancreatic cancer	1.27e-05	0.000135	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PIK3CG—pancreatic cancer	1.26e-05	0.000134	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—NRAS—pancreatic cancer	1.26e-05	0.000134	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—EGF—pancreatic cancer	1.25e-05	0.000133	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—MMP9—pancreatic cancer	1.25e-05	0.000133	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PIK3CG—pancreatic cancer	1.25e-05	0.000133	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—NRAS—pancreatic cancer	1.25e-05	0.000133	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—EGF—pancreatic cancer	1.25e-05	0.000133	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—PTEN—pancreatic cancer	1.25e-05	0.000132	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—EGF—pancreatic cancer	1.24e-05	0.000131	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CCND1—pancreatic cancer	1.24e-05	0.000131	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—TYMS—pancreatic cancer	1.23e-05	0.000131	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CTNNB1—pancreatic cancer	1.22e-05	0.00013	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—AKT1—pancreatic cancer	1.21e-05	0.000129	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—MMP9—pancreatic cancer	1.2e-05	0.000127	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—PTEN—pancreatic cancer	1.19e-05	0.000127	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—AKT1—pancreatic cancer	1.16e-05	0.000124	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PIK3CB—pancreatic cancer	1.16e-05	0.000123	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—EGFR—pancreatic cancer	1.16e-05	0.000123	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—SRC—pancreatic cancer	1.15e-05	0.000123	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—EGFR—pancreatic cancer	1.15e-05	0.000122	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PTGS2—pancreatic cancer	1.15e-05	0.000122	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—EGFR—pancreatic cancer	1.14e-05	0.000121	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—VEGFA—pancreatic cancer	1.12e-05	0.000119	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PIK3CD—pancreatic cancer	1.11e-05	0.000118	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—STAT3—pancreatic cancer	1.11e-05	0.000118	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PIK3CD—pancreatic cancer	1.11e-05	0.000118	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—NRAS—pancreatic cancer	1.11e-05	0.000118	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—SRC—pancreatic cancer	1.11e-05	0.000117	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.1e-05	0.000117	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.1e-05	0.000117	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PIK3CD—pancreatic cancer	1.1e-05	0.000117	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—KRAS—pancreatic cancer	1.09e-05	0.000116	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.09e-05	0.000116	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—KRAS—pancreatic cancer	1.09e-05	0.000115	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—KRAS—pancreatic cancer	1.08e-05	0.000114	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—VEGFA—pancreatic cancer	1.08e-05	0.000114	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—STAT3—pancreatic cancer	1.07e-05	0.000113	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—NRAS—pancreatic cancer	1.06e-05	0.000113	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CD44—pancreatic cancer	1.04e-05	0.00011	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—MYC—pancreatic cancer	1.03e-05	0.00011	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—TGFB1—pancreatic cancer	1.03e-05	0.00011	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—EGFR—pancreatic cancer	1.01e-05	0.000107	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—PIK3CA—pancreatic cancer	1e-05	0.000106	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—APOE—pancreatic cancer	1e-05	0.000106	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PTEN—pancreatic cancer	1e-05	0.000106	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—PIK3CA—pancreatic cancer	1e-05	0.000106	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GCG—pancreatic cancer	9.96e-06	0.000106	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—MYC—pancreatic cancer	9.91e-06	0.000105	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—PIK3CA—pancreatic cancer	9.9e-06	0.000105	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—TGFB1—pancreatic cancer	9.89e-06	0.000105	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PIK3CB—pancreatic cancer	9.72e-06	0.000103	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—EGFR—pancreatic cancer	9.69e-06	0.000103	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PIK3CB—pancreatic cancer	9.69e-06	0.000103	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PIK3CB—pancreatic cancer	9.59e-06	0.000102	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—KRAS—pancreatic cancer	9.56e-06	0.000102	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—STK11—pancreatic cancer	9.36e-06	9.94e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CXCL8—pancreatic cancer	9.34e-06	9.91e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CXCL8—pancreatic cancer	9.31e-06	9.88e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—HRAS—pancreatic cancer	9.28e-06	9.85e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—HRAS—pancreatic cancer	9.25e-06	9.82e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CXCL8—pancreatic cancer	9.22e-06	9.79e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—HRAS—pancreatic cancer	9.16e-06	9.72e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—KRAS—pancreatic cancer	9.16e-06	9.72e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	9.04e-06	9.6e-05	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—AKT1—pancreatic cancer	9.02e-06	9.58e-05	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—AKT1—pancreatic cancer	8.99e-06	9.55e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CASP3—pancreatic cancer	8.94e-06	9.49e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CASP3—pancreatic cancer	8.91e-06	9.46e-05	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—AKT1—pancreatic cancer	8.91e-06	9.45e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CASP3—pancreatic cancer	8.82e-06	9.37e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—PIK3CA—pancreatic cancer	8.79e-06	9.33e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PPARG—pancreatic cancer	8.72e-06	9.26e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CCND1—pancreatic cancer	8.7e-06	9.24e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CCND1—pancreatic cancer	8.67e-06	9.21e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CTNNB1—pancreatic cancer	8.62e-06	9.15e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CCND1—pancreatic cancer	8.59e-06	9.12e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CTNNB1—pancreatic cancer	8.59e-06	9.12e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CTNNB1—pancreatic cancer	8.5e-06	9.03e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—TP53—pancreatic cancer	8.5e-06	9.02e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MMP9—pancreatic cancer	8.45e-06	8.97e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MMP9—pancreatic cancer	8.42e-06	8.94e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—PIK3CA—pancreatic cancer	8.41e-06	8.93e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PTEN—pancreatic cancer	8.4e-06	8.91e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PTEN—pancreatic cancer	8.37e-06	8.89e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MMP9—pancreatic cancer	8.34e-06	8.85e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PTEN—pancreatic cancer	8.29e-06	8.8e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—AKT1—pancreatic cancer	8.19e-06	8.7e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—AKT1—pancreatic cancer	8.17e-06	8.67e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—TP53—pancreatic cancer	8.14e-06	8.64e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—HRAS—pancreatic cancer	8.13e-06	8.63e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—AKT1—pancreatic cancer	8.09e-06	8.58e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—TYMS—pancreatic cancer	8.05e-06	8.55e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	7.95e-06	8.44e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—SRC—pancreatic cancer	7.79e-06	8.27e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—HRAS—pancreatic cancer	7.78e-06	8.26e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—SRC—pancreatic cancer	7.76e-06	8.24e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—SRC—pancreatic cancer	7.69e-06	8.16e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—VEGFA—pancreatic cancer	7.58e-06	8.05e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—VEGFA—pancreatic cancer	7.56e-06	8.03e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—STAT3—pancreatic cancer	7.51e-06	7.97e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—NRAS—pancreatic cancer	7.49e-06	7.95e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—VEGFA—pancreatic cancer	7.49e-06	7.95e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—STAT3—pancreatic cancer	7.49e-06	7.95e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—NRAS—pancreatic cancer	7.47e-06	7.93e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—STAT3—pancreatic cancer	7.41e-06	7.87e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—NRAS—pancreatic cancer	7.4e-06	7.85e-05	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—AKT1—pancreatic cancer	7.18e-06	7.62e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PIK3CA—pancreatic cancer	7.06e-06	7.5e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MYC—pancreatic cancer	6.98e-06	7.41e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—TGFB1—pancreatic cancer	6.96e-06	7.39e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MYC—pancreatic cancer	6.96e-06	7.38e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—TGFB1—pancreatic cancer	6.94e-06	7.37e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	6.93e-06	7.35e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MYC—pancreatic cancer	6.89e-06	7.31e-05	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—AKT1—pancreatic cancer	6.87e-06	7.3e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—TGFB1—pancreatic cancer	6.87e-06	7.29e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PTGS2—pancreatic cancer	6.86e-06	7.29e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—EGFR—pancreatic cancer	6.83e-06	7.25e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—EGFR—pancreatic cancer	6.8e-06	7.22e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—EGFR—pancreatic cancer	6.74e-06	7.15e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—APOE—pancreatic cancer	6.55e-06	6.95e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—KRAS—pancreatic cancer	6.45e-06	6.84e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—KRAS—pancreatic cancer	6.43e-06	6.82e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—KRAS—pancreatic cancer	6.37e-06	6.76e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PTEN—pancreatic cancer	5.99e-06	6.35e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PIK3CA—pancreatic cancer	5.92e-06	6.29e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	5.91e-06	6.27e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PIK3CA—pancreatic cancer	5.91e-06	6.27e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PIK3CA—pancreatic cancer	5.85e-06	6.21e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—AKT1—pancreatic cancer	5.77e-06	6.12e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—TP53—pancreatic cancer	5.73e-06	6.08e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—TP53—pancreatic cancer	5.71e-06	6.06e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PPARG—pancreatic cancer	5.7e-06	6.06e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—TP53—pancreatic cancer	5.66e-06	6.01e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—HRAS—pancreatic cancer	5.48e-06	5.82e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—HRAS—pancreatic cancer	5.46e-06	5.8e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—HRAS—pancreatic cancer	5.41e-06	5.74e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	5.2e-06	5.52e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—AKT1—pancreatic cancer	4.84e-06	5.14e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—AKT1—pancreatic cancer	4.82e-06	5.12e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—AKT1—pancreatic cancer	4.78e-06	5.07e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	4.53e-06	4.81e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PTGS2—pancreatic cancer	4.49e-06	4.76e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	4.22e-06	4.48e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PTEN—pancreatic cancer	3.91e-06	4.15e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—AKT1—pancreatic cancer	3.45e-06	3.66e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	2.76e-06	2.93e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—AKT1—pancreatic cancer	2.26e-06	2.39e-05	CbGpPWpGaD
